Phenotyping the tumor micro-environment with advanced tissue-based multiplexing assays

T cell receptors (TCRs) allow the adaptive immune system to recognize and respond to a vast array of threats, ranging from viruses to malignant cells. Single-cell sequencing has made it possible to explore an individual’s TCR repertoire and quantify changes due to an immune response. To fully unlock the great potential of these measurements we need to know which antigens each TCR binds.

Industry guidelines for host cell protein impurity analysis emphasize the importance of process-specific and product-specific assessment to account for how the purification procedures and the therapeutic product may uniquely influence the impurities observed. HCP-Mass Spectrometry (HCP-MS) analysis is quickly becoming recognized as a practical, orthogonal approach to ELISA to achieve greater coverage and knowledge of the HCP profile of a biopharmaceutical product. Establishing a streamlined workflow for HCP-MS analysis can be challenging, given that the strategies and rationale for implementing HCP-MS will differ depending on the product, process(es) and other project-specific variables. This webinar will highlight the benefits and the limitations of key analysis criteria for scientists who are developing their HCP-MS detection strategy.

Dr. Kristin Comella, Chief Science Officer of U.S. Stem Cell, Inc. a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the successful launch of an open, livestream webinar series designed to inform and educate the public on the benefits and applications of stem cell therapy.

The COVID-19 pandemic has shown the world that the effectiveness of mRNA vaccine technology is undeniable. The potential for these vaccines to efficiently treat a wide range of communicable diseases is enormous, and the technology is poised to explode into the marketplace. However, effective mRNA vaccines are only as good as the materials and methodologies used to create them, as well as the analytical steps used to test their potency, stability, and clinical efficacy. Traditional analytical methods are slow and end up wasting investigators’ time and money. Advanced imaging and analysis platforms may hold the key to simplifying vaccine development and manufacturing bottlenecks, as they are fast and can be multiplexed to answer multiple scientific questions per analysis.